Mylan Completes Expansion of Vermont Transdermal Patch Facility

Article

Mylan completes expansion of its transdermal patch facility in Vermont.

Mylan has completed an 85,000 ft2, three-story expansion project at its transdermal patch facility in St. Albans, Vermont. The facility, operated by Mylan Technologies Inc. (MTI), is a subsidiary of Mylan that focuses on transdermal drug delivery. Mylan's investment includes expanded R&D capabilities and additional manufacturing and laboratory space. In addition, Mylan is in the process of adding more than 160 new positions to its St. Albans-based workforce.

The 14-month expansion project has increased MTI's total operating space to more than 391,000 ft2.

Source: Mylan

Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Samsung Biologics Scores Major Manufacturing Deal Worth Over $1.4 Billion with European Pharma Company

Feliza Mirasol
January 17th 2025
Article

Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Pharmapack Reports on Key Trends for 2025

Feliza Mirasol
January 16th 2025
Article

Pharmapack identifies biologic approvals, drug delivery advancements, GLP-1 generics, and the return of funding flow as drivers for a record year in 2025.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Lonza and Iconovo Team Up on Intranasal Biologic Candidate

Feliza Mirasol
January 15th 2025
Article

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Hikma and Emergent Enter Six-Year Partnership to Sell Naloxone Spray in US and Canada

Patrick Lavery
January 14th 2025
Article

Kloxxado was approved by FDA in 2021 for emergency treatment of opioid overdose, and Emergent also distributes the FDA-approved over-the-counter treatment Narcan.